OncoSec Medical Incorporated President Punit Dhillon Publishes New Blog Post Titled - Why More Biotechs Should ''Go Social''
OncoSec Medical Inc. (OTCBB: ONCS), a company developing its
advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse
therapy to treat solid tumor cancers, published a blog post entitled
“Introduction: Why social-digital now?”
on Mr. Dhillon’s blog site (punitdhillon.com)
which was republished on TheChairmansBlog.com.
OncoSec’s
President and CEO, Punit Dhillon, blogs about how social media has
changed the landscape of communication between patients, doctors and
companies developing therapies for life-threatening conditions. He
highlights the importance of adapting to this change by writing,
“…to be successful, we are aware that we must be novel in our
approach and to take advantage of tools that might not otherwise be
traditionally used by companies in our space.” Mr. Dhillon outlines
what readers can expect from his blog and encourages feedback via
social media.
OncoSec Medical
Inc. is a biopharmaceutical company developing its
advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse
therapy to treat solid tumor cancers. ImmunoPulse and NeoPulse
therapies address an unmet medical need and represent a
potential solution, for less invasive and less expensive therapies
that are able to minimize detrimental effects resulting from
currently available cancer treatments such as surgery, systemic
chemotherapy or immunotherapy and other treatment alternatives.
OncoSec Medical's core technology is based upon its
proprietary use of an electroporation platform
to dramatically enhance the delivery and uptake of a
locally delivered DNA-based immunocytokine (ImmunoPulse) or
chemotherapeutic agent (NeoPulse). Treatment of various
solid cancers using these powerful and targeted anti-cancer
agents has demonstrated selective destruction of cancerous
cells while sparing healthy normal tissues during early and late
stage clinical trials. OncoSec's clinical programs include three
Phase II clinical trials for ImmunoPulse targeting lethal skin
cancers. More information is available at http://www.oncosec.com/.